FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease

FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.

from Health and Science https://ift.tt/anTulAz
https://ift.tt/OilQnbY
https://ift.tt/Rckm6vD